First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.

El Saghir, Nagi S.; Im, Seock\\-Ah; Azim, Hamdy A.; Eralp, Yesim; Yap, Yoon Sim; Sandhu, Malwinder S.; Abdel\\-Razeq, Hikmat; Gupta, Sudeep; Artamonova, Elena; Rihani, Julie; Mora Payan, Juan Carlos; Chattar, Yogesh; Sopher, Gary Mark; Gao, Melissa; Lu, Yen\\-Shen

doi:10.1200/JCO.2025.43.16\_suppl.1069

First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.

Date

2025

Authors

Abdel\\-Razeq, Hikmat

Gupta, Sudeep

Artamonova, Elena

Rihani, Julie

dc.identifier.doi

10.1200/JCO.2025.43.16\_suppl.1069

dc.identifier.other

WOS:001509295600001

Publisher

LIPPINCOTT WILLIAMS \& WILKINS

DOI

10.1200/JCO.2025.43.16\_suppl.1069

URI

https://openaccess.acibadem.edu.tr/handle/11443/4975

Collections

WOS

Full item page

First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By